Cullinan Oncology Ownership | Who Owns Cullinan Oncology?
Cullinan Oncology Ownership Summary
Cullinan Oncology is owned by 53.90% institutional investors, 4.55% insiders, and 41.55% retail investors. Bioimpact capital is the largest institutional shareholder, holding 13.06% of CGEM shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.84% of its assets in Cullinan Oncology shares.
CGEM Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Cullinan Oncology | 53.90% | 4.55% | 41.55% |
| Sector | Healthcare Stocks | 279.18% | 10.62% | -189.80% |
| Industry | Biotech Stocks | 63.96% | 10.74% | 25.30% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Bioimpact capital | 7.65M | 13.06% | $57.90M |
| Bvf inc/il | 5.75M | 9.82% | $43.53M |
| Blackrock | 3.55M | 8.25% | $61.92M |
| Blackrock funding, inc. /de | 4.37M | 7.49% | $53.24M |
| Deerfield management company, l.p. (series c) | 3.86M | 6.59% | $29.23M |
| Lynx1 capital management lp | 3.22M | 5.49% | $24.34M |
| Vanguard group | 2.94M | 5.03% | $35.76M |
| Blue owl capital lp | 2.37M | 4.06% | $28.88M |
| Kynam capital management, lp | 2.34M | 3.99% | $17.70M |
| Franklin resources | 2.20M | 3.77% | $26.79M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Bioimpact capital | 7.65M | 9.95% | $57.90M |
| Lynx1 capital management lp | 3.22M | 8.72% | $24.34M |
| Blue owl capital lp | 2.37M | 6.65% | $28.88M |
| Patient square capital lp | 878.90K | 2.75% | $6.65M |
| Foresite capital management vi | 634.56K | 2.63% | $4.80M |
| Nextech invest | 1.14M | 2.25% | $13.90M |
| Bvf inc/il | 5.75M | 1.77% | $43.53M |
| Kynam capital management, lp | 2.34M | 1.49% | $17.70M |
| Twin focus capital partners | 595.49K | 1.07% | $7.25M |
| Vr adviser | 1.38M | 0.89% | $10.45M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Lynx1 capital management lp | 3.22M | 8.72% | 1.96M |
| Blackrock | 3.55M | 0.00% | 1.12M |
| Kynam capital management, lp | 2.34M | 1.49% | 1.09M |
| Artal group | 1.06M | 0.47% | 1.06M |
| Boxer capital | 657.89K | 0.60% | 657.89K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Paradigm biocapital advisors lp | - | - | -2.32M |
| Holocene advisors, lp | - | - | -1.53M |
| Cormorant asset management, lp | - | - | -1.13M |
| Adage capital partners gp | - | - | -1.03M |
| Logos global management lp | - | - | -700.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Artal group | 1.06M | 0.47% | 1.06M | $18.45M |
| Boxer capital | 657.89K | 0.60% | 657.89K | $11.47M |
| Woodline partners lp | 167.31K | 0.01% | 167.31K | $2.04M |
| Voss capital | 122.36K | 0.11% | 122.36K | $1.49M |
| Bnp paribas arbitrage, snc | 115.00K | 0.00% | 115.00K | $1.40M |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -5.00 |
| Srs capital advisors | -7.00 |
| Capital performance advisors llp | -13.00 |
| Rothschild investment | -60.00 |
| Bessemer group | -105.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 19 | -87.25% | 31,573,885 | -51.85% | 53 | 0.43% | 6 | -92.68% | 5 | -86.11% |
| Dec 31, 2024 | 78 | -45.07% | 19,633,373 | -69.80% | 33 | 0.27% | 44 | -48.24% | 22 | -21.43% |
| Sep 30, 2024 | 142 | 3.65% | 65,005,696 | 3.31% | 111 | 0.85% | 85 | -14.14% | 28 | 12.00% |
| Jun 30, 2024 | 136 | 18.26% | 62,925,233 | 59.82% | 146 | 1.73% | 98 | 60.66% | 25 | -30.56% |
| Mar 31, 2024 | 115 | 1.77% | 39,373,046 | 6.88% | 92 | 1.24% | 61 | -11.59% | 36 | 56.52% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.68M | 2.84% | - |
| Vanguard US Total Market Shares ETF | 1.50M | 2.57% | - |
| iShares Russell 2000 ETF | 1.35M | 2.29% | 660.00 |
| Franklin Biotechnology Discv A(acc)USD | 842.14K | 1.43% | - |
| Vanguard Institutional Extnd Mkt Idx Tr | 818.11K | 1.39% | 2.22K |
| Franklin Small Cap Growth Adv | 785.04K | 1.33% | - |
| Franklin US Small Cap Growth Equity | 785.04K | 1.33% | -6.52K |
| AB Small Cap Growth A | 771.98K | 1.31% | -11.45K |
| SPDR® S&P Biotech ETF | 619.99K | 1.05% | 801.00 |
| Fidelity Small Cap Index | 514.67K | 0.87% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 25, 2025 | Jones Jeffrey Alan | Chief Medical Officer | Sell | $41.75K |
| Feb 25, 2025 | AHMED NADIM | President and CEO | Sell | $106.87K |
| Feb 25, 2025 | Michaelson Jennifer | Chief Scientific Officer | Sell | $32.04K |
| Feb 25, 2025 | SUMER JACQUELYN L | Chief Legal Officer | Sell | $32.04K |
| Jan 06, 2025 | Michaelson Jennifer | Chief Scientific Officer | Sell | $50.04K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | - | 5 |
| 2024 Q4 | - | 6 |
| 2024 Q3 | - | 2 |
| 2024 Q2 | - | 3 |
| 2024 Q1 | - | 5 |
CGEM Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools